Table 3.

Survival from metastatic diagnosis and sites of progression for hormone receptor-positive patients by first-line treatment

Data are n (%) unless otherwise noted. In all, 26 HR-positive patients (4 who received hormonal therapy only, 11 who received trastuzumab plus chemotherapy, and 3 who received trastuzumab plus chemotherapy plus hormonal therapy) and 28 HR-negative patients had PD recorded on or before initiation of treatment for metastatic breast cancer. For these patients, progression-free survival was calculated from time of metastatic diagnosis to the first PD recorded after initiation of metastatic treatment. If hormone therapy and chemotherapy overlapped for at least 30 consecutive days, patients were assigned to the concurrent use subgroup; otherwise, they were assigned to the sequential use subgroup.

^aDeath occurred before any disease progression.

Abbreviations: HR, hormone receptor; NR, not reached; PD, progressive disease.